Literature DB >> 11389804

Anxiety Disorders in Neurologic Illness.

Robert D. Davies1, Sherri L. Gabbert, Paula D. Riggs.   

Abstract

Anxiety disorders frequently occur in individuals with neurologic illness. Anxiety may be a symptom of or a reaction to the neurologic disorder, a medication side effect, or a comorbid condition. The most common anxiety disorders seen in neurologic patients are panic disorder, generalized anxiety disorder, social phobia, and obsessive-compulsive disorder (OCD). Very often, these conditions go unrecognized (and therefore untreated) or are attributed to being a normal response to having a neurologic illness. However, if they are not treated, anxiety disorders can significantly increase morbidity and mortality in neurologic patients. Selective serotonin reuptake inhibitors (SSRIs) should be considered the first-line of pharmacologic treatment, because they offer a broad spectrum of efficacy in the anxiety disorders, are generally well tolerated, and are effective in treating comorbid depression. Benzodiazepines, although most effective for acute anxiety, are now considered adjunctive or second-line treatments. Cognitive behavioral therapy and other behavioral treatments are effective in the treatment of anxiety disorders. They should be considered primary treatments for patients who cannot tolerate or prefer not to take medications.

Entities:  

Year:  2001        PMID: 11389804     DOI: 10.1007/s11940-001-0038-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  74 in total

1.  A therapeutic approach to children and adolescents with anxiety disorders and associated comorbid conditions.

Authors:  K Manassis; S Monga
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-01       Impact factor: 8.829

2.  Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.

Authors:  D Baldwin; J Bobes; D J Stein; I Scharwächter; M Faure
Journal:  Br J Psychiatry       Date:  1999-08       Impact factor: 9.319

Review 3.  The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings.

Authors:  M G Kushner; K Abrams; C Borchardt
Journal:  Clin Psychol Rev       Date:  2000-03

4.  An open-label trial of nefazodone in high comorbidity panic disorder.

Authors:  N A DeMartinis; E Schweizer; K Rickels
Journal:  J Clin Psychiatry       Date:  1996-06       Impact factor: 4.384

Review 5.  Anxiety and Parkinson's disease.

Authors:  I H Richard; R B Schiffer; R Kurlan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

Review 6.  Anxiety disorders in children and adolescents: a review of the past 10 years.

Authors:  G A Bernstein; C M Borchardt; A R Perwien
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-09       Impact factor: 8.829

7.  Depression in substance-dependent delinquents.

Authors:  P D Riggs; S Baker; S K Mikulich; S E Young; T J Crowley
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1995-06       Impact factor: 8.829

8.  Anxiety disorders in patients with Parkinson's disease.

Authors:  M B Stein; I J Heuser; J L Juncos; T W Uhde
Journal:  Am J Psychiatry       Date:  1990-02       Impact factor: 18.112

Review 9.  Diagnostic and treatment implications of psychiatric comorbidity with migraine.

Authors:  P E Keck; K R Merikangas; S L McElroy; S M Strakowski
Journal:  Ann Clin Psychiatry       Date:  1994-09       Impact factor: 1.567

View more
  5 in total

1.  Specific phobia is a frequent non-motor feature in stiff man syndrome.

Authors:  P Henningsen; H-M Meinck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

2.  Substance Use Disorders and Neurologic Illness.

Authors:  Robert D. Davies; Christian Thurstone; Kelly Woyewodzic
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

3.  Anxiety disorders in headache patients in a specialised clinic: prevalence and symptoms in comparison to patients in a general neurological clinic.

Authors:  D Mehlsteibl; C Schankin; P Hering; P Sostak; A Straube
Journal:  J Headache Pain       Date:  2011-02-06       Impact factor: 7.277

4.  Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications.

Authors:  Stefano Pallanti; Giacomo Grassi; Elisa Dinah Sarrecchia; Andrea Cantisani; Matteo Pellegrini
Journal:  Front Psychiatry       Date:  2011-12-21       Impact factor: 4.157

5.  Pharmacologic management of anxiety and affective lability during recovery from Guillain-Barré syndrome: some preliminary observations.

Authors:  Kristin Brousseau; David Arciniegas; Susie Harris
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.